Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at ZAR 2.39T, ahead of Pfizer (ZAR 2.12T) and Johnson & Johnson (ZAR 2.05T). Figures as of 20 Nov 2026, 10:09 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieZAR 2.39T
- Median
- ZAR 14.5B
- Combined market value
- ZAR 65.11T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | ZAR 2.39T | ZAR 8.74T | ZAR 4,941.92 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | ZAR 2.12T | ZAR 2.74T | ZAR 480.00 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | ZAR 2.05T | ZAR 11.21T | ZAR 4,656.08 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | ZAR 1.5T | ZAR 20.98T | ZAR 23,549.16 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | ZAR 1.47T | ZAR 5.71T | ZAR 2,314.79 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | ZAR 1.25T | ZAR 2.08T | ZAR 1,016.83 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | ZAR 591.6B | ZAR 3.14T | ZAR 1,810.39 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | ZAR 391.8B | ZAR 397.2B | ZAR 346.50 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | ZAR 211.5B | ZAR 572.1B | ZAR 1,408.12 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | ZAR 172.7B | ZAR 678.7B | ZAR 1,180.32 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | ZAR 162.1B | ZAR 1.66T | ZAR 16,093.23 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | ZAR 121.6B | ZAR 2.3T | ZAR 9,074.77 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | ZAR 118.7B | ZAR 229B | ZAR 458.22 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | ZAR 72.8B | ZAR 345.1B | ZAR 2,576.41 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | ZAR 64B | ZAR 129.9B | ZAR 372.81 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | ZAR 54.1B | ZAR 84.9B | ZAR 1,016.57 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | ZAR 52.9B | ZAR 79B | ZAR 474.43 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | ZAR 52.5B | ZAR 265.4B | ZAR 1,362.63 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | ZAR 36.3B | ZAR 124.9B | ZAR 896.91 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | ZAR 26.6B | ZAR 552.4B | ZAR 2,517.85 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | ZAR 26.3B | ZAR 207.4B | ZAR 1,070.51 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | ZAR 15.4B | ZAR 107.6B | ZAR 760.79 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | ZAR 13.7B | ZAR 415B | ZAR 9,744.76 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | ZAR 12.8B | ZAR 54.4B | ZAR 280.61 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | ZAR 11.4B | ZAR 160.6B | ZAR 6,914.92 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | ZAR 10.5B | ZAR 124.4B | ZAR 2,364.82 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | ZAR 9.5B | ZAR 100B | ZAR 5,001.18 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | ZAR 9.2B | ZAR 108.7B | ZAR 1,664.68 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | ZAR 8.5B | ZAR 80.8B | ZAR 841.84 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | ZAR 7.2B | ZAR 170.9B | ZAR 1,130.82 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | ZAR 5.3B | ZAR 84.1B | ZAR 483.49 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | ZAR 3.7B | ZAR 141.1B | ZAR 2,035.75 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | ZAR 3.3B | ZAR 124B | ZAR 1,132.56 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | ZAR 1.9B | ZAR 70.3B | ZAR 513.82 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | ZAR 1.6B | ZAR 147.3B | ZAR 184.23 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | ZAR 1.2B | ZAR 87B | ZAR 247.85 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | ZAR 1.1B | ZAR 161.6B | ZAR 1,701.63 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | ZAR 1B | ZAR 151.5B | ZAR 5,418.79 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | ZAR 932.1M | ZAR 141.1B | ZAR 2,161.59 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | ZAR 654M | ZAR 83.3B | ZAR 1,478.53 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | ZAR 528.9M | ZAR 78.6B | ZAR 717.57 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | ZAR 290.8M | ZAR 115.3B | ZAR 1,700.58 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | ZAR 175.5M | ZAR 106.9B | ZAR 2,632.18 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | ZAR 159.6M | ZAR 91.5B | ZAR 2,168.04 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 17.4294 ZAR).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (ZAR 2.39T), Pfizer (ZAR 2.12T) and Johnson & Johnson (ZAR 2.05T) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 10:09 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of ZAR 65.11T as of 20 Nov 2026, 10:09 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.